Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia: early-phase trial registry
1 of 1 indexed Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count
Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia: 1 US clinical trial tracked, 1 recruiting.
Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Akiva Mintz, running 1 of these trials.
Enrollment posture brief
Registry condition alzheimer39s-disease-mild-cognitive-impairment-other-forms-of-dementia
OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia is recruiting above its size-band peers.
1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia page
1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Akiva Mintz sponsors the most Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia trials on record, review their full trial history before evaluating a specific study. See Akiva Mintz's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia condition card totals 1 registered trials; most-linked intervention 18F-Florbetapir or 18F-Flutemetamol; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.